logo-loader
viewPhagoMed Biopharma

PhagoMed looks to raise around $18M to scale up its bacterial infections treatment

PhagoMed Biopharma GmbH CEO Alexander Belcredi spoke with Proactive at the Biotech Showcase 2020 in San Francisco. The Austria-based biotech's pipeline is focused on treating biofilm-forming bacterial infections, which are all in preclinical development. The company specializes in fighting multi-resistant bacteria, where multiple antibiotics have become ineffective.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Ceres Power eyes expansion following new Bosch deal

This month German engineering firm Bosch increased its stake in Ceres Power Holdings (LON:CWR) to around 18% from 4% following a share subscription, netting Ceres £38mln. It was Bosch that approached Ceres too, pinpointing Ceres steel fuel cell technology as potentially the best in the...

3 hours, 33 minutes ago

2 min read